Skip to main content

Table 3 Clinical, microbiological, and global responses at the end of all treatment

From: Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial

Parameter MITT population PP population
Clinical response, % [n/N]
Success (95% CI) 76.2 (60.5–87.9) [32/42] 82.4 (65.5–93.2) [28/34]
Cure 64.3 [27/42] 67.6 [23/34]
Improvement 11.9 [5/42] 14.7 [5/34]
Failurea 4.8 [2/42] 5.9 [2/34]
Indeterminate 14.3 [6/42] 5.9 [2/34]
Not assessed 4.8 [2/42] 5.9 [2/34]
Microbiological response, % [n/N]
Success (95% CI) 81.0 (65.9–91.4) [34/42] 82.4 (65.5–93.2) [28/34]
Eradication 73.8 [31/42] 73.5 [25/34]
Presumed eradication 7.1 [3/42] 8.8 [3/34]
Failure 2.4 [1/42] 2.9 [1/34]
Not assessed 16.7 [7/42] 14.7 [5/34]
Global response, % [n/N]
Success (95% CI) 73.8 (58.0–86.1) [31/42] 79.4 (62.1–91.3) [27/34]
Failure 11.9 [5/42] 8.8 [3/34]
Not assessed 14.3 [6/42] 11.8 [4/34]
  1. Abbreviations used: CI, confidence interval; MITT, modified intent-to-treat; PP, per protocol.